Metastatic melanoma has a median length of survival after diagnosis of 6–9 months. Unfortunately, the National Comprehensive Cancer Network clinical practice guidelines for treating stage IV, unresectable, metastatic melanoma are limited with regard to treatment options. Pazopanib (Votrient™) is FDA-approved for advanced soft tissue sarcoma and advanced renal cell carcinoma. Limited research exists for using pazopanib in the treatment of metastatic melanoma. We present five cases in which pazopanib was used in combination with paclitaxel ± carboplatin for treatment of unresectable, metastatic melanoma.
BalchCMSoongSJGershenwaldJE. Prognostic factors analysis of 17,600 melanoma patients: validation of the american joint committee on cancer melanoma staging system. J Clin Oncol2001; 19: 3622–3634.
TanARDowlatiAJonesSF. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist2010; 15: 1253–1261.
HurwitzHIDowlatiASainiS. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res2009; 15: 4220–4227.
7.
BurrisHADowlatiAMossRA. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther2012; 11: 1820–1828.
8.
JacobsCKimDStrakaC. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. JCO2013; 31: pp. e114–e117.
9.
MinochaMKhuranaVMitraAK. Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). J Chromatogr B Analyt Technol Biomed Life Sci2012; 901: 85–92.
10.
IwamotoFMLambornKRRobinsHI. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American brain tumor consortium study 06–02). Neuro-Oncology2010; 12: 855–861.
11.
FruehaufJLutzkyJMcDermottD. Multicenter, phase II study of axitinib, a selective second- generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res2011; 17: 7462–7469.
12.
KimKBSosmanJAFruehaufJP. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol2012; 30: 34–41.
13.
Fruehauf JP, Alger B, Parmakhtiar B, et al. A phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma: interim analysis. J Clin Oncol 2012; 30(suppl; abstr8524), 2012 ASCO Annual Meeting.
14.
Phase II trial of pazopanib (GW786034) in pre-treated and untreated metastatic melanoma patients. Clinical trials.gov (this study is ongoing, but not recruiting participants). Sponsor: National Cancer Institute (NCI).
15.
A phase II, single-arm study of pazopanib and paclitaxel as first line treatment for subjects with unresectable stage III and stage IV melanoma. Clinical trials.gov (this study is currently recruiting participants). Sponsor: University of California, Irvine. Collaborator: GlaxoSmithKline.
